Diabetes Metab J.  2017 Feb;41(1):38-50. 10.4093/dmj.2017.41.1.38.

Application of the 2013 American College of Cardiology/American Heart Association Cholesterol Guideline to the Korean National Health and Nutrition Examination Surveys from 1998 to 2012

• Song YS
• Oh TJ
• Kim KM
• Moon JH
• Choi SH
• Jang HC
• Park KS
• Lim S

• KMID: 2368528
• DOI: http://doi.org/10.4093/dmj.2017.41.1.38

Abstract

BACKGROUND
The 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline for the treatment of blood cholesterol recommends statin therapy for individuals at high risk of atherosclerotic cardiovascular disease (ASCVD). The aim of this study was to investigate serial trends in the percentages of Korean adults considered eligible for statin therapy according to the new ACC/AHA cholesterol guideline.
METHODS
Data from the Korean National Health and Nutrition Examination Survey (KNHANES) I (1998, n=7,698), II (2001, n=5,654), III (2005, n=5,269), IV (2007 to 2009, n=15,727), and V (2010 to 2012, n=16,304), which used a stratified, multistage, probability sampling design, were used as representative of the entire Korean population.
RESULTS
The percentage of adults eligible for statin therapy according to the ACC/AHA cholesterol guideline increased with time: 17.0%, 19.0%, 20.8%, 20.2%, and 22.0% in KNHANES I, II, III, IV, and V, respectively (P=0.022). The prevalence of ASCVD was 1.4% in KNHANES I and increased to 3.3% in KNHANES V. The percentage of diabetic patients aged 40 to 75 years with a low density lipoprotein cholesterol levels of 70 to 189 mg/dL increased from 4.8% in KNHANES I to 6.1% in KNHANES V. People with an estimated 10-year ASCVD risk ≥7.5% and aged 40 to 75 years accounted for the largest percentage among the four statin benefit groups: 9.1% in KNHANES I and 11.0% in KNHANES V.
CONCLUSION
Application of the 2013 ACC/AHA guideline has found that the percentage of Korean adults in the statin benefit groups has increased over the past 15 years.

Keyword

American Heart Association; Atherosclerosis; Cardiovascular disease; Guideline; Korea

MeSH Terms

Adult
American Heart Association
Atherosclerosis
Cardiovascular Diseases
Cholesterol*
Cholesterol, LDL
Heart*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Korea
Nutrition Surveys
Prevalence
Cholesterol
Cholesterol, LDL

Figure

• 

  Fig. 1 Annual changes in the percentages of adults in the 1998 to 2012 Korean National Health and Nutrition Examination Surveys (KNHANESs) eligible for 4 statin benefit groups based on the 2013 American College of Cardiology/American Heart Association lipid guideline. ASCVD, atherosclerotic cardiovascular disease; LDL-C, low density lipoprotein cholesterol.

• 

  Fig. 2 Age-specific distributions of adults in the 1998 to 2012 Korean National Health and Nutrition Examination Surveys (KNHANESs) eligible for statin treatment based on the 2013 American College of Cardiology/American Heart Association lipid guideline.

Reference

1. World Health Organization. World health statistics 2015. updated 2015 May 14. Available from: http://www.who.int/gho/publications/world_health_statistics/2015/en/index.html.

2. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63(25 Pt B):2889–2934.

3. Institute for Health Metrics and Evaluation (IHME). Global burden of disease study 2013 (GBD 2013). updated 2015 Mar 10. Available from: http://ghdx.healthdata.org.

4. Statistics Korea. Annual report on the causes of death statistics 2014. updated 2015 Sep 23. Available from: http://www.kostat.go.kr.

5. Ueshima H, Sekikawa A, Miura K, Turin TC, Takashima N, Kita Y, Watanabe M, Kadota A, Okuda N, Kadowaki T, Nakamura Y, Okamura T. Cardiovascular disease and risk factors in Asia: a selected review. Circulation. 2008; 118:2702–2709.

6. Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Flaxman A, Murray CJ, Naghavi M. The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation. 2014; 129:1493–1501.

7. Kweon S, Kim Y, Jang MJ, Kim Y, Kim K, Choi S, Chun C, Khang YH, Oh K. Data resource profile: the Korea National Health and Nutrition Examination Survey (KNHANES). Int J Epidemiol. 2014; 43:69–77.

8. Lim S, Shin H, Song JH, Kwak SH, Kang SM, Won Yoon J, Choi SH, Cho SI, Park KS, Lee HK, Jang HC, Koh KK. Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007. Diabetes Care. 2011; 34:1323–1328.

9. Kim KM, Choi SH, Lim S, Moon JH, Kim JH, Kim SW, Jang HC, Shin CS. Interactions between dietary calcium intake and bone mineral density or bone geometry in a low calcium intake population (KNHANES IV 2008-2010). J Clin Endocrinol Metab. 2014; 99:2409–2417.

10. Lee YH, Kim SU, Song K, Park JY, Kim DY, Ahn SH, Lee BW, Kang ES, Cha BS, Han KH. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: nationwide surveys (KNHANES 2008-2011). Hepatology. 2016; 63:776–786.

11. Warnick GR, Knopp RH, Fitzpatrick V, Branson L. Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem. 1990; 36:15–19.

12. Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA. 2015; 314:1818–1831.

13. Chia YC, Lim HM, Ching SM. Validation of the pooled cohort risk score in an Asian population: a retrospective cohort study. BMC Cardiovasc Disord. 2014; 14:163.

14. Roh E, Ko SH, Kwon HS, Kim NH, Kim JH, Kim CS, Song KH, Won JC, Kim DJ, Choi SH, Lim S, Cha BY. Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association. Prevalence and management of dyslipidemia in Korea: Korea National Health and Nutrition Examination Survey during 1998 to 2010. Diabetes Metab J. 2013; 37:433–449.

15. OECD. Pensions at a glance 2015: OECD and G20 indicators. Paris: OECD Publishing;2015. updated 2015 Dec 1. Available from: http://dx.doi.org/10.1787/pension_glance-2015-en.

16. Huang ES, Basu A, O'Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care. 2009; 32:2225–2229.

17. Korean Diabetes Association. Korean diabetes fact sheet in Korea 2015. Seoul: Korea Diabetes Association;2015.

18. Ha KH, Kim DJ. Trends in the diabetes epidemic in Korea. Endocrinol Metab (Seoul). 2015; 30:142–146.

19. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med. 2007; 357:1477–1486.

20. Heart Protection Study Collaborative Group. Bulbulia R, Bowman L, Wallendszus K, Parish S, Armitage J, Peto R, Collins R. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet. 2011; 378:2013–2020.

21. Kasai T, Miyauchi K, Kurata T, Satoh H, Ohta H, Tanimoto K, Kawamura M, Okazaki S, Yokoyama K, Kojima T, Akimoto Y, Daida H. Long-term (11-year) statin therapy following percutaneous coronary intervention improves clinical outcome and is not associated with increased malignancy. Int J Cardiol. 2007; 114:210–217.

22. Lloyd SM, Stott DJ, de Craen AJ, Kearney PM, Sattar N, Perry I, Packard CJ, Briggs A, Marchbank L, Comber H, Jukema JW, Westendorp RG, Trompet S, Buckley BM, Ford I. Long-term effects of statin treatment in elderly people: extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). PLoS One. 2013; 8:e72642.

23. JBS3 Board. Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart. 2014; 100:Suppl 2. ii1–ii67.

24. The ARIC investigators. The Atherosclerosis Risk in Communities (ARIC) study: design and objectives. Am J Epidemiol. 1989; 129:687–702.

25. MPH for the Cardiovascular Health Study Research Group (CHS). Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, O'Leary DH, Psaty B, Rautaharju P. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991; 1:263–276.

26. Friedman GD, Cutter GR, Donahue RP, Hughes GH, Hulley SB, Jacobs DR Jr, Liu K, Savage PJ. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol. 1988; 41:1105–1116.

27. Dawber TR, Kannel WB, Lyell LP. An approach to longitudinal studies in a community: the Framingham Study. Ann N Y Acad Sci. 1963; 107:539–556.

28. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol. 1979; 110:281–290.

29. Li YF, Feng QZ, Gao WQ, Zhang XJ, Huang Y, Chen YD. The difference between Asian and Western in the effect of LDL-C lowering therapy on coronary atherosclerotic plaque: a meta-analysis report. BMC Cardiovasc Disord. 2015; 15:6.

30. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y. MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006; 368:1155–1163.

31. Nohara R, Daida H, Hata M, Kaku K, Kawamori R, Kishimoto J, Kurabayashi M, Masuda I, Sakuma I, Yamazaki T, Yokoi H, Yoshida M. Justification For Atherosclerosis Regression Treatment (JART) Investigators. JART) Investigators. Effect of long-term intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness: Justification for Atherosclerosis Regression Treatment (JART) extension study. Circ J. 2013; 77:1526–1533.